GSK Pakistan - Making a Difference Globally

Making a Global Difference

Lymphatic Filariasis (LF):

LF, also known as elephantiasis, is a mosquito-transmitted disease that can lead to a chronic swelling of arms, legs, breasts or genitals. It is one of the principal causes of permanent disability globally and more than 120 million people in Asia, Africa and Latin America are affected.

GSK is a founder member of the Global Alliance to Eliminate LF. This alliance is the largest public health drug donation initiative in history, in terms of numbers of people treated. It will also be the single largest donation programme in the pharmaceutical industry ever. The initiative aims to treat over 1 billion people annually for 5 consecutive years. GSK and the Global Alliance received international recognition once again in 2006 and as one of ten recipients of a prestigious World Business Award, the LF programme was recognised for its contribution to achieving the UN Millennium Development Goals. GSK provides grants of almost £1 million and staff expertise to support the coalition-building, training and communication activities of the Global Alliance to eliminate LF.

Personal Hygeine And Sanitation Education (PHASE)

Every year over 2.2 million people, mostly children in developing countries, die of diarrhoeal disease all over the world. This disease is one of the world's biggest killers, yet one of the most easily preventable. PHASE is a simple handwashing program for schoolchildren that saves lives. Initiated by GSK in 1998 after identifying personal hygiene and sanitation as a neglected health education priority, PHASE is transforming personal hygiene and sanitation by taking a holistic approach to healthcare, education, community development, water and sanitation.

International Programme for HIV Education "Positive Action Programme"

It is estimated that more than 36 million adults and children are living with HIV/AIDS with approximately 15,000 more people being infected each day. Globally, more than 21 million people have died from AIDS, resulting in 13.2 million orphaned children.

Positive Action is GSK's international programme of HIV education, care and community support. In this, GSK works in partnership with individuals, community groups, healthcare providers, international agencies and others to encourage HIV prevention as well as education, care and treatment of people living with, or affected by HIV/AIDS. Since its inception in 1992, positive action supported and implemented a wide variety of projects at both national and international levels throughout the world.